What is HC Wainwright’s Forecast for Korro Bio Q1 Earnings?

Korro Bio, Inc. (NASDAQ:KRRO) – Investment analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Korro Bio in a research note issued to investors on Tuesday, May 19th. HC Wainwright analyst M. Kapoor anticipates that the company will earn ($1.54) per share for the quarter. HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($5.63) per share. HC Wainwright also issued estimates for Korro Bio’s Q2 2027 earnings at ($1.51) EPS, Q3 2027 earnings at ($1.55) EPS, Q4 2027 earnings at ($1.62) EPS and FY2027 earnings at ($6.23) EPS.

Korro Bio (NASDAQ:KRRO) last issued its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.60) by ($0.09). Korro Bio had a negative return on equity of 117.86% and a negative net margin of 1,834.48%.

A number of other analysts have also issued reports on KRRO. Weiss Ratings reiterated a “sell (d-)” rating on shares of Korro Bio in a research note on Wednesday, April 8th. William Blair upgraded Korro Bio from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 17th. Wall Street Zen upgraded Korro Bio from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Clear Str raised Korro Bio from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 18th. Finally, Raymond James Financial raised shares of Korro Bio from a “market perform” rating to an “outperform” rating and set a $23.00 price target for the company in a research report on Friday, March 13th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.71.

Korro Bio Stock Performance

Shares of NASDAQ:KRRO opened at $9.15 on Wednesday. The business’s 50-day simple moving average is $12.31 and its 200 day simple moving average is $12.05. The company has a market cap of $131.87 million, a P/E ratio of -0.78 and a beta of 3.07. Korro Bio has a one year low of $5.20 and a one year high of $55.89.

Institutional Investors Weigh In On Korro Bio

Several large investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. bought a new position in shares of Korro Bio during the third quarter worth about $39,000. Wells Fargo & Company MN raised its holdings in shares of Korro Bio by 45.5% during the fourth quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock valued at $60,000 after buying an additional 2,352 shares during the last quarter. Guggenheim Capital LLC acquired a new position in shares of Korro Bio during the fourth quarter worth approximately $84,000. Jain Global LLC bought a new stake in Korro Bio during the 4th quarter valued at $85,000. Finally, Deutsche Bank AG raised its stake in Korro Bio by 241.9% during the 4th quarter. Deutsche Bank AG now owns 12,758 shares of the company’s stock valued at $102,000 after acquiring an additional 9,027 shares in the last quarter. 13.18% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Korro Bio

In other Korro Bio news, major shareholder Paul Edward Walker bought 207,100 shares of the stock in a transaction on Tuesday, March 10th. The stock was purchased at an average price of $11.11 per share, for a total transaction of $2,300,881.00. Following the completion of the purchase, the insider directly owned 1,297,893 shares in the company, valued at approximately $14,419,591.23. This trade represents a 18.99% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Forest Baskett purchased 207,100 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was acquired at an average cost of $11.11 per share, with a total value of $2,300,881.00. Following the completion of the acquisition, the insider directly owned 1,297,893 shares in the company, valued at approximately $14,419,591.23. This trade represents a 18.99% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders acquired 1,657,320 shares of company stock worth $18,412,560. 4.80% of the stock is owned by insiders.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.